Pfizer: presents new data on Relugolix
(CercleFinance.com) - Myovant Sciences and Pfizer today announced the presentation of new data from clinical studies of a once-daily combination therapy of relugolix (40 mg), estradiol (1 mg) and norethindrone acetate (0.
5 mg) in premenopausal women with uterine fibroids and in women with endometriosis pain.
"These studies provide important new data for relugolix combination therapy, including detailed two-year efficacy and safety data in women with heavy menstrual bleeding associated with uterine fibroids," said Juan Camilo Arjona Ferreira, Chief Medical Officer of Myovant Sciences.
"They also provide additional insight into the potential effect of relugolix combination therapy in women with pain associated with endometriosis".
Pfizer shares are currently up over 1.5% on Wall Street.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
5 mg) in premenopausal women with uterine fibroids and in women with endometriosis pain.
"These studies provide important new data for relugolix combination therapy, including detailed two-year efficacy and safety data in women with heavy menstrual bleeding associated with uterine fibroids," said Juan Camilo Arjona Ferreira, Chief Medical Officer of Myovant Sciences.
"They also provide additional insight into the potential effect of relugolix combination therapy in women with pain associated with endometriosis".
Pfizer shares are currently up over 1.5% on Wall Street.
Copyright (c) 2021 CercleFinance.com. All rights reserved.